TC Medical(SH:600763) Sou Hu Cai Jing·2025-12-11 12:24Core Viewpoint - Tongce Medical (600763) reported a slight decline in stock price and mixed capital flow data, indicating potential investor caution despite modest revenue and profit growth in recent quarters [1][2]. Group 1: Stock Performance - As of December 11, 2025, Tongce Medical's stock closed at 40.42 yuan, down 1.85% with a turnover rate of 0.96% and a trading volume of 43,100 hands, resulting in a transaction amount of 176 million yuan [1]. - On December 11, the net outflow of main funds was 30.99 million yuan, accounting for 17.66% of the total transaction amount, while retail investors saw a net inflow of 22.60 million yuan, representing 12.88% of the total [1]. Group 2: Financial Performance - For the first three quarters of 2025, Tongce Medical reported a main revenue of 2.29 billion yuan, a year-on-year increase of 2.56%, and a net profit attributable to shareholders of 514 million yuan, up 3.16% year-on-year [2]. - In Q3 2025, the company achieved a single-quarter main revenue of 842 million yuan, reflecting a 2.34% year-on-year increase, with a net profit of 192 million yuan, up 2.31% year-on-year [2]. - The company's debt ratio stands at 25.1%, with investment income of 41.22 million yuan and financial expenses of 31.93 million yuan, while the gross profit margin is reported at 41.69% [2]. Group 3: Analyst Ratings - Over the past 90 days, seven institutions have provided ratings for Tongce Medical, with four giving a "buy" rating and three an "increase" rating [2]. - The average target price set by institutions in the last 90 days is 5.29 yuan [2].